150
Participants
Start Date
January 9, 2020
Primary Completion Date
May 8, 2025
Study Completion Date
April 30, 2026
Toraymyxin PMX 20R Extracorporeal Hemoperfusion Cartridge
TORAYMYXIN PMX-20R (PMX) is an extracorporeal hemoperfusion cartridge intended for the selective removal of endotoxin from circulating blood through direct hemoperfusion (DHP). Each treatment will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 mL/minute, (range of 80 to 120 mL/minute).
Mt Sinai Hospital, New York
Stony Brook University, Stony Brook
UPMC, Pittsburgh
George Washington University, Washington D.C.
Medical University of South Carolina, Charleston
Emory University, Atlanta
CHI Memorial, Chattanooga
Parkridge Hospital, Chattanooga
University of Michigan, Ann Arbor
Mayo Clinic, Rochester
Louisiana State University Health Shreveport, Shreveport
University of Arkansas for Medical Sciences, Little Rock
The University of Texas Health Science Center at Houston, Houston
Institute for Extracorporeal Life Support, San Antonio
Pulmonary Associates, Boulder
University of California, San Francisco, San Francisco
University of Alabama at Birmingham, Birmingham
Baystate Medical Center, Springfield
Cooper Health System, Camden
Rutgers, The State University of New Jersey, Piscataway
Spectral Diagnostics (US) Inc.
INDUSTRY